Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan

The Tohoku Journal of Experimental Medicine
Y YamasakiT Kaneko

Abstract

We evaluated the effect of pioglitazone, a thiazolidinedione compound, on insulin-stimulated glucose disposal (Rd) and its efficacy on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus (NIDDM). Twenty NIDDM subjects (mean age 58.2+/-9.4 year, body mass index (BMI) 23.9+/-3.4 kg/ m2 (mean+/-S.D.], three with diet alone, 17 with sulfonylureas [SU]) participated in this trial from five diabetes clinics. Euglycemic (5.3 mmol/liter) hyperinsulinemic (insulin infusion rate 9 micromoles x kg[-1] x min[-1]) clamp studies were performed before and after oral administration of pioglitazone (30 mg/day) for 87+/-10 days. The Rd significantly improved from 5.5+/-2.5 to 8.3+/-3.1 mg x kg(-1) x min(-1). Fasting plasma glucose (FPG) level significantly decreased from 11.0+/-2.0 mmol/liter to 8.9+/-1.1 mmol/liter with a significant improvement in the hemoglobin A1c level from 9.2+/-1.8% to 8.3+/-1.5%. Fasting serum insulin and C peptide levels decreased from 83+/-36 pmol/liter and 0.62+/-0.21 nmol/liter to 66+/-29 pmol/liter and 0.58+/-0.25 nmol/liter, respectively. Fasting serum triglyceride and free fatty acids levels significantly decreased with concomitant increase of fasting serum HDL-cholesterol le...Continue Reading

References

Aug 10, 1989·The New England Journal of Medicine·J ErikssonL Groop
Aug 1, 1994·Diabetic Medicine : a Journal of the British Diabetic Association·K MimuraH Nawata
Aug 1, 1993·Journal of Internal Medicine·S Efendic, C G Ostenson
Jul 1, 1995·Diabetes Research and Clinical Practice·M SekiyaT Kamada
Jun 14, 1996·Biochemical and Biophysical Research Communications·T HayakawaH Ikeda

❮ Previous
Next ❯

Citations

Mar 29, 2002·Diabetes/metabolism Research and Reviews·Harold E Lebovitz
Feb 7, 2004·Current Diabetes Reports·Martha L Cruz, Michael I Goran
Jan 1, 2003·Comprehensive Therapy·Biswanath P GoudaVivian A Fonseca
Sep 6, 2003·The American Journal of Cardiology·Vivian A Fonseca
Dec 1, 2001·Endocrinology and Metabolism Clinics of North America·H E Lebovitz
Jan 22, 2003·Trends in Cardiovascular Medicine·P Zimmet
Dec 22, 1999·British Journal of Pharmacology·L C PickavanceJ P Wilding
Nov 1, 2001·Diabetes, Obesity & Metabolism·P Arner
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Sunil AsnaniVivian A Fonseca
Feb 17, 2007·American Journal of Therapeutics·Intekhab AhmedBarry J Goldstein
Sep 20, 2006·International Journal of Clinical Practice·J Wilding
Jun 28, 2007·International Journal of Clinical Practice. Supplement·M Hanefeld
Jul 3, 2002·Drugs·Fabrice M A C MartensTon J Rabelink
Jun 3, 2005·Clinical Medicine & Research·Michael T Sheehan
Nov 30, 2000·Biochemical and Biophysical Research Communications·J SakamotoH Sawada
Jun 1, 2001·Journal of Endocrinological Investigation·R Perfetti, K Chamie
Sep 8, 2007·Canadian Journal of Physiology and Pharmacology·Anita MehtaRamesh Goyal
Dec 23, 2003·Current Medical Research and Opinion·Hiroaki SeinoRyuzo Abe
Apr 2, 2004·International Journal of Clinical Practice·I W Campbell
Apr 16, 2011·Journal of Veterinary Pharmacology and Therapeutics·J M G WearnL J McCutcheon
May 4, 2005·Journal of Diabetes and Its Complications·Giancarlo Viberti
Jan 8, 2005·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·A Herrera-ArellanoJ Tortoriello
Feb 13, 2001·Annual Review of Medicine·S Mudaliar, R R Henry
May 23, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·J J NolanL F Deacon
May 25, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·T M WallaceD R Matthews
Sep 29, 2005·Current Diabetes Reports·Riccardo Perfetti, Eugenio D'Amico
Jul 12, 2005·Endocrine Journal·Toshio KaharaShuichi Kaneko
Aug 9, 2001·Coronary Artery Disease·S RosenblattUNKNOWN Pioglitazone 026 Study Group
Apr 12, 2003·British Journal of Clinical Pharmacology·Klemens BuddeDavid Eckland
Jun 4, 1999·Drug Discovery Today·H Shinkai
Jul 20, 2004·Reproductive Biomedicine Online·David A Ehrmann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.